Replies to post #216590 on Biotech Values

[GD]

PTLA: more points to cover
Yes, Eliquis, Xarelto, and Pradaxa are well-entrenched in the marketplace,
but patients taking Eliquis or Xarelto are very aware of the bleeding risk
which cause 15K death a year, ICH mortality rate of 35% to 45%. As a PTLA
investor, we would love to see PTLA to do PIII trials Bevyxxa Vs Eliquis on
all Eliquis's indications, even with non-superior primary end, but major
bleed as one of the secondary end points, IF Bevyxxa pass the efficacy
primary end with a SS secondary bleeding end point, most patients will
demand Bevyxxa Drs have no reason to refuse, look at other way, Bevyxxa
market share may be decided by patients demand, IMO.